RNAV8 Bio lands part of $4.4M ARPA-H grant for programmable RNA medicines

What's the deal? RNAV8 BioDealroom has a profile for this one. Try Dealroom → has been selected for a one-year ARPA-H pilot grant of up to $4.4 million to develop programmable RNA medicines. The Cambridge, Massachusetts biotech joins a team led by the Rouskin Lab at Harvard Medical SchoolDealroom has a profile for this one. Try Dealroom →, with the Weissman Lab at MIT and the Whitehead InstituteDealroom has a profile for this one. Try Dealroom →.

What's the endgame? The program, called PROPEL, aims to control gene expression through RNA structure. The goal is logic-gated RNA therapies that switch on only where and when intended, without altering the genome.

How it works: An RNA molecule's untranslated regions fold into structures that set how much protein it produces. When a small molecule binds one of those folds, the structure rearranges and output changes — turning a dose into a dial on protein expression. Bacteria use this logic in elements called riboswitches; in human cells it remains largely uncharted.

RNAV8 Bio focuses on the therapeutic format itself: screening protein output from mRNA pools, engineering UTRs in the delivery format, and validating results at the cargo level. That includes driving cell-type-selective expression of payloads such as gene-editing enzymes or CAR constructs.

What they're saying: "The promise of mRNA has always been that it's programmable, but in practice the relationship between an RNA's sequence and chemistry and what it actually does has been hard to predict," said Devan Shah, founder and chief executive officer of RNAV8 Bio.

The program is led by ARPA-H program manager Shannon Greene. "Human cells almost certainly already use this kind of structural control; we've simply never had the tools to find it systematically," said Silvi Rouskin, assistant professor of microbiology at Harvard Medical School. "PROPEL is our attempt to map it and put it to work."

The signal: At up to $4.4 million, the award sits in the top 10% of health grant rounds in the US by size. That scale — backed by ARPA-H — points to rising government appetite for early-stage bets that could reshape how RNA medicines are designed and controlled.

Image credit: RNAV8 Bio